Gefitinib is Used for treating patients with metastatic non-small cell lung cancer (NSCLC) with specific EGFR mutations. It was first introduced by Astrazeneca Uk Ltd in its drug Iressa on May 5, 2003. 6 different companies have introduced drugs containing Gefitinib.

Gefitinib Patents

Given below is the list of patents protecting Gefitinib, along with the drug name that holds that patent and the company name owning that drug.

Download patent list as spreadsheet

Get the complete list right in your inbox!

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Iressa	US5770599	Quinazoline derivatives	May 05, 2017 (Expired)	Astrazeneca
Iressa	US5770599	Quinazoline derivatives	May 05, 2017 (Expired)	Astrazeneca
Iressa	US5457105	Quinazoline derivatives useful for treatment of neoplastic disease	Jan 19, 2013 (Expired)	Astrazeneca
Iressa	US5616582	Quinazoline derivatives as anti-proliferative agents	Jan 19, 2013 (Expired)	Astrazeneca

Add above patents to watchlist

Gefitinib's Family Patents

Full family tree

Gefitinib Generic API Manufacturers

Several generic applications have been filed for Gefitinib. The first generic version for Gefitinib was by Apotex Inc and was approved on Sep 23, 2022. And the latest generic version is by Cipla Ltd and was approved on May 16, 2025.

Given below is the list of companies who have filed for Gefitinib generic, along with the locations of their manufacturing plants worldwide.